Allopurinol in Patients with Diabetes and LVH

• Research type

  Research Study

• Full title

  Do Xanthine Oxidase Inhibitors Regress Left Ventricular Hypertrophy in Diabetes?

• Sponsor organisation

  University of Dundee

• Eudract number

  2008-008485-12

• Research summary

  Left ventricular hypertrophy (LVH, thickening of heart muscle) independently confers high risk of cardiovascular events. High blood pressure is the other factor in the development of LVH and many diabetic patients have normal blood pressure and LVH. Therefore a new way needs to be found to reduce LVH in diabetic patients with normal blood pressure. Oxidative stress appears to be a major mediator in developing LVH. Allopurinol is known to be potent at reducing oxidative stress and therefore may be a way of reducing LVH and endothelial function in diabetic patients. If this study is successful then Allopurinol may become an important medication in reducing LVH and improving mortality in diabetic patients with LVH.Microvolt T wave alternans (MTWA) is going to be used to assess if Allopurinol reduces arrythmogenicity. It has been used once before in study by Dr AM Choy within the University of Dundee. MTWA is thought to reflect arrythmogenicity (Gehi et al 2005, Bloomfield et al 2006, Hennersdorf et al 2001).

• REC name

  East of Scotland Research Ethics Service REC 2

• REC reference

  09/S0501/3

• Date of REC Opinion

  25 Feb 2009

• REC opinion

  Further Information Favourable Opinion